MedTrace Logo

Study in Healthy Volunteers to Investigate the Effects of Rifampin on the Pharmacokinetics of NKTR-118

NCT01533870 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2014-10-15

No results posted yet for this study

Summary

Study in healthy volunteers to investigate the effects of Rifampin on the Pharmacokinetics of NKTR-118.

Conditions

  • Drug Induced Constipation

Interventions

DRUG

NKTR-118

Oral 25 mg

DRUG

Rifampin

Oral 600 mg

Sponsors & Collaborators

Principal Investigators

  • Bo Fransson, MD · AstraZeneca, Sodertalje Sweden

  • Kelli Craven, MD · Quintiles, Inc Kansas Overland Park US.

  • Mark Sostek, MD · AstraZeneca, Wilmington US

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01533870 on ClinicalTrials.gov